• Japanese
  • Korean
  • Chinese
Cover Image

Lung Cancer Partnering 2009-2014

The ‘Lung Cancer Partnering 2009-2014’ report provides understanding and access to the lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in lung cancer partnering deals
  • Top lung cancer deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type

Description

The report provides an analysis of lung cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lung cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains over 200 links to online copies of actual lung cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of lung cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in lung cancer partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading lung cancer deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of lung cancer partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of lung cancer technologies and products.

Report scope

‘Lung Cancer Partnering 2009-2014’ is intended to provide the reader with an in-depth understanding and access to lung cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in lung cancer dealmaking in the biopharma industry since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 200 lung cancer contract documents
  • The leading lung cancer deals by value since 2009

In ‘Lung Cancer Partnering 2009-2014’, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

‘Lung Cancer Partnering 2009-2014’ provides the reader with the following key benefits:

  • In-depth understanding of lung cancer deal trends since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 200 actual lung cancer deals entered into by the world's biopharma companies since 2009
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in lung cancer partnering

  • 2.1. Introduction
  • 2.2. Lung cancer partnering over the years
  • 2.3. Bigpharma lung cancer dealmaking activity
  • 2.4. Lung cancer partnering by deal type
  • 2.5. Lung cancer partnering industry sector
  • 2.6. Lung cancer partnering by stage of development
  • 2.7. Lung cancer partnering by technology type
  • 2.8. Disclosed financial deal terms for lung cancer partnering
    • 2.8.1. Lung cancer headline values
    • 2.8.2. Lung cancer upfront payments
    • 2.8.3. Lung cancer milestone payments
    • 2.8.4. Lung cancer royalty rates

Chapter 3 - Leading lung cancer deals

  • 3.1. Introduction
  • 3.2. Top lung cancer deals by value
  • 3.3. Top lung cancer deals involving bigpharma

Chapter 4 - Dealmaking directory

  • 4.1. Introduction
  • 4.2. Company A-Z
  • 4.3. By deal type
    • Asset purchase
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Contract service
    • Co-promotion
    • CRADA
    • Cross-licensing
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Grant
    • Joint venture
    • Licensing
    • Manufacturing
    • Marketing
    • Option
    • Promotion
    • Research
    • Settlement
    • Spin out
    • Sub-license
    • Supply
    • Termination
  • 4.4. By industry sector
    • Academic
    • Bigpharma
    • Biotech
    • Drug delivery
    • Medical device
    • Diagnostic
    • Generic pharma
    • Government
    • Non-profit
    • Pharmaceutical
    • Research tools
    • Services
    • Specialty pharma
  • 4.5. By stage of development
    • Discovery
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
    • Registration
    • Marketed
  • 4.6. By technology type
    • Analysis
    • Animal models
    • Assays
    • Bioinformatics
    • Biological compounds
    • Biomarkers
    • Biomaterials
    • Cell culture
    • Cell therapy
    • Clinical testing
    • Diagnostic - companion
    • Devices
    • Diagnostics
    • Discovery tools
    • DNA probes
    • Drug delivery
    • Enabling technology
    • Epigenetics
    • Equipment
    • Facilities
    • Gene therapy
    • Genomics
    • Imaging
    • Industrial chemicals
    • In vitro models
    • Monoclonal antibodies
    • Nanotechnology
    • Oligonucleotide
    • Peptides
    • Personalised medicine
    • Processes
    • Proteomics
    • Radio/Chemo-therapy
    • Recombinant DNA
    • Research services
    • Research supplies
    • RNA therapeutics
    • Screening
    • Small molecules
    • Stem cells
    • Vaccines

Chapter 5 - Partnering resource center

  • 5.1. Online partnering
  • 5.2. Partnering events
  • 5.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports

Table of Figures

  • Figure 1: Lung cancer partnering since 2009
  • Figure 2: Bigpharma - top 50 - lung cancer deals 2009 to 2011
  • Figure 3: Bigpharma lung cancer deal frequency - 2009 to 2011
  • Figure 4: Lung cancer partnering by deal type since 2009
  • Figure 5: Lung cancer partnering by industry sector since 2009
  • Figure 6: Lung cancer partnering by stage of development since 2009
  • Figure 7: Lung cancer partnering by technology type since 2009
  • Figure 8: Lung cancer deals with a headline value
  • Figure 9: Lung cancer deals with upfront payment values
  • Figure 10: Lung cancer deals with milestone payments
  • Figure 11: Lung cancer deals with royalty rates, %
  • Figure 12: Top lung cancer deals by value since 2009
  • Figure 13: Top lung cancer deals signed by bigpharma value since 2009
  • Figure 14: Online partnering resources
  • Figure 15: Forthcoming partnering events
  • Figure 16: Deal type definitions
Show More
Pricing
Get Notified
Email me when related reports are published